Agree 100% here. There's still a decent market for IIH. IMO, they will proceed with the trial either way.
Given that recruitment has been slow, they had two options - (1) to just proceed with the trial as it is and waste SHs time and money (likely raising of more capital) or (2) pivot and seek approval to change the secondary endpoint to allow peeps outside of the current PMD limits to enrol, which means a lower sample size and a cash and timeline neutral situation. So, as the trial ticks along with the current eligibility criteria, we can continue to recruit and wait for the market analysis.
Re: the market analysis - we need to better understand what the issue is with having the other GLPs available, when Presendin is designed to be significantly more effective in lowering ICP (it's quicker and longer lasting). Do they believe that more women being prescribed these GLPs will mean lower rates of obesity going forward, which will lower the incidence of IIH in the future? They used the term "acceptability" of Presendin. They needed to be clearer on this point.
- Forums
- ASX - By Stock
- Ann: Phase III Clinical Trial Update and New IIH Market Analysis
Agree 100% here. There's still a decent market for IIH. IMO,...
-
- There are more pages in this discussion • 111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
Add IXC (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 6.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.8¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.062 |
1 | 15500 | 0.061 |
1 | 150000 | 0.060 |
1 | 100000 | 0.052 |
1 | 60001 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.068 | 10000 | 1 |
0.069 | 16500 | 1 |
0.070 | 40000 | 1 |
0.076 | 888 | 1 |
0.083 | 4000 | 1 |
Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
IXC (ASX) Chart |
Day chart unavailable